ClinPhone acquisition boosts Parexel's guidance
This article was originally published in Scrip
Parexel Internationalhas raised its revenue guidance for the first-quarter of fiscal 2009, ending September 30th, from $260-270 million to $270-280 million, following the close of its acquisition of the clinical technology organisation ClinPhone last month (ScripOnline, August 19th, 2008). The company has also raised its fiscal 2009 revenue guidance from $1.13-1.16 billion to $1.22-1.25 billion. Parexel expects to earn $10-14 million in first-quarter revenue from the acquisition and $95-105 million in full-year revenue. Parexel hopes that the acquisition of ClinPhone will enhance its eClinical platform and will absorb the newly acquired firm into its technology subsidiary Perceptive Informatics.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.